TEVA.N Teva Pharmaceutical Industries Limited Sponsored ADR

Teva Statement on European Commission Decision; Company to Appeal

Teva Statement on European Commission Decision; Company to Appeal

  • Teva Pharmaceuticals disagrees with the European Commission decision, which is based on legal theories that the company believes are extreme, untested, and factually unsupported
  • The company intends to appeal the outcome and is fully prepared to mount its defense
  • Teva has supported the MS community since 1996 and will not be distracted from providing access to this important standard-of-care treatment
  • Teva works to the highest ethical standards with all our external experts and do so in a highly regulated environment

TEL AVIV, Israel, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals Industries Ltd. (NYSE: and TASE: TEVA) is responding to the  following its investigation into the company’s practices regarding COPAXONE® -- the standard-of-care treatment for multiple sclerosis – and announcing its intention to appeal the judgement and fine imposed.

The company is deeply disappointed by this decision and has been cooperating extensively with the EC since 2019. Teva disagrees with the Commission’s legal theories which are legally untested and, Teva believes, not supported by the facts. The company will vigorously defend its position on appeal and is well prepared financially to mount a defense.

Teva conducts its business lawfully and ethically and has been a strong partner to Europe, its patients, economy and healthcare systems. This misguided decision will not distract Teva from its unwavering support for patients living with MS and their families.

Media Contacts:

Kelley Dougherty (973) 832-2810

Eden Klein +972 (3) 906 2645   



EN
31/10/2024

Underlying

TEVA.NTeva Pharmaceutical Industries Limited Sponsored ADR

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Teva Pharmaceutical Industries Limited Sponsored ADR

 PRESS RELEASE
Free
TEVA.N Teva Pharmaceut...

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The F...

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine FDA approves single-dose AJOVY® (fremanezumab-vfrm) injection for the preventive treatment of episodic migraine in children and adolescents aged 6-17 who weigh 45 kilograms or more, offering a long-awaited monthly treatment option with in-office or at-home administration1AJOVY expands access across age groups as the first and only calcitonin gene-related peptide (CGRP) antagonist approved for pediatric episodic migraine prevention and migraine prevention ...

August 6, 2025 1 EN
Si Yong Ng
  • Si Yong Ng
Free Trial
TEVA.N Teva Pharmaceut...

Teva - Earnings Flash - Q2 FY 2025 Results - Lucror Analytics

Teva has reported good Q2/25 numbers, with adjusted EBITDA rising y-o-y. While reported sales were broadly flat, they would have increased if adjusting for the disposal of the Japan business venture (BV). Cash generation improved. Reported net leverage was broadly flat q-o-q, while liquidity remained adequate. We anticipate decent H2/25 results, with continued top-line-supported growth in Austedo, Ajovy and Uzedy to offset headwinds from the Japan BV disposal. Profitability should benefit fr...

TEVA.N TEVA PHARMACEUTICAL INDUSTRIES LIMITED SPONSORED ADR
07/31/25 July 31, 2025 1 EN
Josseline Jenssen ... (+2)
  • Josseline Jenssen
  • Si Yong Ng
Free Trial
TEVA.N Teva Pharmaceut...

Lucror Analytics - Convertibles Brief

In today's Convertibles Brief publication we comment on developments of the following high yield issuers: GOL, Teva

TEVA.N TEVA PHARMACEUTICAL INDUSTRIES LIMITED SPONSORED ADR
07/31/25 July 31, 2025 1 EN
Felix Fischer ... (+7)
  • Felix Fischer
  • Haidje Rustau
  • Jayanth Kandalam
  • Peter Low
  • Si Yong Ng
  • Tanvi Arora
  • Trung Nguyen
Free Trial
CO Casino Guichar...
TEVA.N Teva Pharmaceut... ... (+9)

Lucror Analytics - Morning Views Europe

In today's Morning Views publication we comment on developments of the following high yield issuers: Trivium, Applus, Altice France (SFR), Casino Guichard-Perrachon, International Personal Finance, TeamSystem, Aston Martin, Virgin Media O2, Liberty Global, TalkTalk, Recordati, Tata Motors, Nexans, Italmatch Chemicals, Itelyum Group, Teva

CO CASINO GUICHARD-PERRACHON SA
TEVA.N TEVA PHARMACEUTICAL INDUSTRIES LIMITED SPONSORED ADR
LBTYA LIBERTY GLOBAL PLC CLASS A
NEX NEXANS SA
IPF INTERNATIONAL PERSONAL FINANCE PLC
REC RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.
TALK TALKTALK TELECOM GROUP PLC
TATAMOTORS TATA MOTORS LIMITED
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS PLC
07/31/25 July 31, 2025 1 EN
 PRESS RELEASE
Free
TEVA.N Teva Pharmaceut...

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth i...

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy.Q2 2025 shows 10th consecutive quarter of year-over-year (YoY) revenue growth; Revenues of $4.2 billion, +1% in local currencyterms (“LC“)excluding Japan BV revenues; United States segment +2%; Europe segment +3% in LC; International Markets segment -4% inLCand excluding Japan BV revenues. Innovative portfolio continu...

July 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch